(2018) have verified the cardioprotective effects exerted by the inactivation of the p38-MAPK/NF-κB pathways with the involvement of Irbesartan against polymicrobial sepsis, a systemic inflammatory response usually correlated with several organ failures, possibly by attenuating myocardial dysfunction and reducing pro-inflammatory cytokines [12]. Here, NFKB1 is linked to Sepsis.